The tumor microenvironment and immune responses in prostate cancer patients

The landscape of cancer treatment has been transformed over the past decade by the success of immune-targeting therapies. However, despite sipuleucel-T being the first-ever approved vaccine for cancer and the first immunotherapy licensed for prostate cancer in 2010, immunotherapy has since seen limi...

Full description

Saved in:
Bibliographic Details
Published inEndocrine-related cancer Vol. 28; no. 8; pp. T95 - T107
Main Authors Kwon, J T W, Bryant, R J, Parkes, E E
Format Journal Article
LanguageEnglish
Published England Bioscientifica Ltd 01.08.2021
Society for Endocrinology & BioScientifica Ltd
Subjects
Cancer therapies
Cancer vaccines
Fibroblasts
Genomics
Humans
Immune system
Immunity
Immunotherapy
Lymphocytes T
Male
Metastases
Prostate cancer
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Solid tumors
Thematic Review
Tumor Microenvironment
personalised medicine
molecular subgroup
prostate
tumour microenvironment
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:The landscape of cancer treatment has been transformed over the past decade by the success of immune-targeting therapies. However, despite sipuleucel-T being the first-ever approved vaccine for cancer and the first immunotherapy licensed for prostate cancer in 2010, immunotherapy has since seen limited success in the treatment of prostate cancer. The tumour microenvironment of prostate cancer presents particular barriers for immunotherapy. Moreover, prostate cancer is distinguished by being one of only two solid tumours where increased T cell-infiltration correlates with a poorer, rather than improved, outlook. Here, we discuss the specific aspects of the prostate cancer microenvironment that converge to create a challenging microenvironment, including myeloid-derived immune cells and cancer-associated fibroblasts. By exploring the immune microenvironment of defined molecular subgroups of prostate cancer, we propose an immunogenomic subtyping approach to single-agent and combination immune-targeting strategies that could lead to improved outcomes in prostate cancer treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This paper is part of a thematic review section celebrating 80 Years of Androgen Deprivation as a Treatment for Prostate Cancer. The guest editors for this section were Amina Zoubeidi and Paramita Ghosh.
ISSN:1351-0088
1479-6821
DOI:10.1530/ERC-21-0149